Posts Tagged: dr. portnoy

20 West Physicians Named Castle Connolly Top Docs

Posted by & filed under Uncategorized.

🏆 20 West physicians have been named Castle Connolly Top Doctors 🏆 Castle Connolly’s Top Docs represent the ✨top 7%✨ of all U.S. practicing physicians! Selected through a rigorous process of peer nominations and thorough vetting by a physician-led research team, these doctors are truly top-notch healthcare providers. Their exceptional clinical care, specialty expertise, and… Read more »

Brain Tumors

Posted by & filed under Uncategorized.

At West Cancer Center & Research Institute, our multi-disciplinary team works with exceptional neurosurgical groups to provide specialized care for individuals diagnosed with brain cancer. 25,050 new cases are identified each year in the US, but our team manages this frightening disease with personalized care plans for all brain tumor types including brain metastasis, glioblastoma,... Read more »

Skin Cancer

Posted by & filed under Uncategorized.

As the largest organ in the body, your skin performs so many key functions from protection from the environment to infection control. Our skin cancer team at West Cancer Center & Research Institute is trained to manage all forms of skin cancer with the latest clinical trials, immunotherapy and targeted therapy. We have specialists that... Read more »

Sarcoma

Posted by & filed under Uncategorized.

Although sarcomas are rare, representing only 1% of cancer types, at West Cancer Center & Research Institute, we have a team that specializes in treating this form of cancer. Our sarcoma team manages soft tissue tumors, which comprise approximately 80% of all sarcomas and bone tumors. Our multidisciplinary team works together to diagnosis the specifics... Read more »

David Portnoy, MD, FACP Previews Immunotherapy Breakthroughs – Shaking Up Frontline SCLC Paradigm

Posted by & filed under Uncategorized.

Click here to view this full article on OncLive.com.    The addition of immune checkpoint inhibitors to chemotherapy has led to durable responses and improved survival without increased toxicity in patients with small cell lung cancer (SCLC), according to David C. Portnoy, MD, FACP, who added that biomarkers of response to this approach and a… Read more »